Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosisalfapump® is ...

Regular coffee consumption (2-3 cups/day) protects against liver cirrhosis, reduces fibrosis, prevents liver cancer, and ...

Trans- versus cisgender adults have an increased prevalence of cirrhosis but similar five-year survival, according t ...

Biomarker staging of liver fibrosis in hepatitis C was cost effective, but so was initiating treatment without testing.

Control Blood Pressure and Cholesterol High blood pressure and cholesterol are significant risk factors for heart disease.

The alfapump is approved by the US FDA for the treatment of recurrent or refractory ascites due to liver cirrhosis. It is the first active implantable medical device in the US that automatically and ...

Causes of compensated cirrhosis may include nonalcoholic fatty liver disease (NAFLD), alcohol-related liver disease, and chronic hepatitis B and C. Treatment for the condition will depend on the ...

Sequana Medical Announces US FDA Approval of alfapump® for the Treatment of Recurrent or Refractory Ascites due to Liver Cirrhosis KOL Webcast on January 8, 2025 – 3pm CET, 9am ET The Company ...

In advanced cirrhosis, liver transplantation may become the only viable treatment option. The persistent liver damage and cirrhosis significantly increase the risk of developing liver cancer.

Background and Aims: Neuropathy in association with chronic liver disease, including cirrhosis, is recognized; however, there are differences in the incidence and type of neuropathy reported.